|
|
|
| Clinical Efficacy and Safety of Etanercept Combined with Methotrexate in Treatment of Moderate to Severe Rheumatoid Arthritis |
| HUANG Yuan |
| Department of Rheumatology and Immunology, Guangyuan Central Hospital, Guangyuan , Sichuan, China 628000 |
|
|
|
|
Abstract 【Objective】To study the clinical efficacy and safety of etanercept combined with methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis (RA) . 【Methods】Eighty-four cases of severe RA patients were randomly divided into experimental group (etanercept + methotrexate) and control group (hormone + methotrexate), 42 cases in each group.The clinical efficacy and side effects of the two groups were compared after 24 weeks of continuous treatment.【Results】After 24 weeks of treatment, the synovial membrane thicknesss of erythrocyte sedimentation rate (ESR), C reactive protein (CRP), rheumatoid factor (RF), disease activity score (DAS28) and wrist, the second and third metacarpophalangeal joints (MCP2,3), the second and third proximal interphalangeal joints (PIP2,3) and the knee of the two groups were lower than those before treatment (P＜0.05),and the experimental group was more significant than the control group (P＜0.05);The efficacy of ACR20, ACR50 and ACR70 in the experimental group were 83.33% (35/42), 61.90% (26/42), and 42.86% (18/42),and that of the control group were 76.19% (32/42),47.62% (20/42), 21.43% (9/42); the efficiency of ACR70 in the experimental group was higher than that of the control group (P＜0.05);The incidence of adverse reactions in the experimental group was 26.19%, which was higher than that in the control group (19.05%) (P＜0.05).【Conclusion】Etanercept combined with methotrexate has better clinical outcome in treatment of severe active RA , but the incidence of adverse is higher.
|
|
Received: 26 February 2017
|
|
|
|
|
|
[1]Hussain S, Abood S, Gorial F. The adjuvant use of calcium fructoborate and borax with etanercept in patients with rheumatoid arthritis: Pilot study[J].J Intercul Ethnopharmacol,2017,6(1):58-61.
[2] Lan JL, Tseng CH, Chen JH,et al.Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-alpha inhibitor[J].Medicine (Baltimore),2017,96(7):6055-6056.
[3] 庞丽霞. 益赛普联合甲氨蝶呤治疗类风湿关节炎的临床效果观察[J].中国实用医药,2016,0(17):206-207.
[4] 赵颖,苑晓娟,孟力平. 甲氨蝶呤联合益赛普治疗类风湿风湿关节炎[J].山西大同大学学报(自然科学版),2014,30(03):52-54.
[5] 张磊. 益赛普联合甲氨蝶呤治疗类风湿关节炎的作用机制[J].中国老年学杂志,2014(12):3338-3339.
[6] 郭立霞,徐育冬,王浩,等. 肿瘤坏死因子受体-抗体融合蛋白对佐剂性关节炎大鼠滑膜中TNF-α、TGF-β1和VEGF表达的影响[J].河北医药,2014,36(07):969-971.
[7] 王利. 益赛普治疗类风湿关节炎25例疗效观察[J].中国实用医药,2016(25):32-34.
[8] 宫肇玉,余河庆,夏文春. 类风湿关节炎应用关节腔内注射治疗的效果探讨[J].世界最新医学信息文摘,2015,0(88):132-134.
[9] Verazza S, Davi S, Consolaro A,et al.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept[J].Pediatr Rheumatol Online J,2016,14(1):68-71. |
|
|
|
2017, Vol. 34 
